SG11201407228PA - N-aryltriazole compounds as lpar antagonists - Google Patents
N-aryltriazole compounds as lpar antagonistsInfo
- Publication number
- SG11201407228PA SG11201407228PA SG11201407228PA SG11201407228PA SG11201407228PA SG 11201407228P A SG11201407228P A SG 11201407228PA SG 11201407228P A SG11201407228P A SG 11201407228PA SG 11201407228P A SG11201407228P A SG 11201407228PA SG 11201407228P A SG11201407228P A SG 11201407228PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- compounds
- designated states
- drive
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 241000867614 Mimus polyglottos Species 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661953P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062463 WO2013189865A1 (en) | 2012-06-20 | 2013-06-17 | N-aryltriazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407228PA true SG11201407228PA (en) | 2014-12-30 |
Family
ID=48628669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407228PA SG11201407228PA (en) | 2012-06-20 | 2013-06-17 | N-aryltriazole compounds as lpar antagonists |
Country Status (22)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140067048A (ko) | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | 라이소포스파티드산 수용체 길항제 |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| AU2014232383B2 (en) | 2013-03-15 | 2019-01-17 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| ES2824801T3 (es) | 2014-06-27 | 2021-05-13 | Ube Industries | Sal de compuesto heterocíclico sustituido con halógeno |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| WO2018078009A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2018087126A1 (en) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives as inhibitors of tankyrase |
| CN107827829A (zh) * | 2017-11-07 | 2018-03-23 | 大连理工大学 | 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法 |
| CN107721984A (zh) * | 2017-11-07 | 2018-02-23 | 大连理工大学 | 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法 |
| WO2019126098A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| KR102756637B1 (ko) | 2017-12-19 | 2025-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산 |
| EP3728209A1 (en) | 2017-12-19 | 2020-10-28 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| KR102697358B1 (ko) | 2017-12-19 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
| JP7256807B2 (ja) * | 2017-12-19 | 2023-04-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール |
| EP3728216B1 (en) | 2017-12-19 | 2023-09-06 | Bristol-Myers Squibb Company | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| ES2938863T3 (es) | 2017-12-19 | 2023-04-17 | Bristol Myers Squibb Co | Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA) |
| MX2020005323A (es) | 2017-12-19 | 2020-08-13 | Bristol Myers Squibb Co | Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). |
| JP7212047B2 (ja) | 2017-12-19 | 2023-01-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434653A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20230019880A (ko) | 2020-06-03 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN118541360A (zh) | 2021-12-08 | 2024-08-23 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| CN115745848A (zh) * | 2022-12-07 | 2023-03-07 | 上海优合生物科技有限公司 | 一种氨基胍的加工合成工艺 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| JP2014508111A (ja) * | 2010-12-07 | 2014-04-03 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| KR20140067048A (ko) * | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | 라이소포스파티드산 수용체 길항제 |
| UA109868C2 (ru) * | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) |
-
2013
- 2013-06-17 UA UAA201500426A patent/UA110310C2/uk unknown
- 2013-06-17 AU AU2013279513A patent/AU2013279513A1/en not_active Abandoned
- 2013-06-17 EP EP13729332.0A patent/EP2864301A1/en not_active Withdrawn
- 2013-06-17 MA MA37762A patent/MA37762B1/fr unknown
- 2013-06-17 IN IN9352DEN2014 patent/IN2014DN09352A/en unknown
- 2013-06-17 BR BR112014030674A patent/BR112014030674A2/pt not_active Application Discontinuation
- 2013-06-17 HK HK15106924.1A patent/HK1206339A1/xx unknown
- 2013-06-17 KR KR1020147035551A patent/KR20150011389A/ko not_active Ceased
- 2013-06-17 JP JP2015517705A patent/JP2015520203A/ja active Pending
- 2013-06-17 MX MX2014014711A patent/MX2014014711A/es unknown
- 2013-06-17 WO PCT/EP2013/062463 patent/WO2013189865A1/en active Application Filing
- 2013-06-17 CN CN201380031806.0A patent/CN104395299A/zh active Pending
- 2013-06-17 PE PE2014002213A patent/PE20142305A1/es not_active Application Discontinuation
- 2013-06-17 SG SG11201407228PA patent/SG11201407228PA/en unknown
- 2013-06-17 US US14/403,261 patent/US20150133512A1/en not_active Abandoned
- 2013-06-17 CA CA2869564A patent/CA2869564A1/en not_active Abandoned
- 2013-06-17 EA EA201492281A patent/EA201492281A1/ru unknown
-
2014
- 2014-10-22 PH PH12014502363A patent/PH12014502363A1/en unknown
- 2014-11-07 ZA ZA2014/08167A patent/ZA201408167B/en unknown
- 2014-11-20 CO CO14255124A patent/CO7131357A2/es unknown
- 2014-11-28 CL CL2014003241A patent/CL2014003241A1/es unknown
- 2014-12-04 IL IL236087A patent/IL236087A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015520203A (ja) | 2015-07-16 |
| PH12014502363A1 (en) | 2015-01-12 |
| MX2014014711A (es) | 2015-03-04 |
| PE20142305A1 (es) | 2015-01-16 |
| ZA201408167B (en) | 2015-12-23 |
| EP2864301A1 (en) | 2015-04-29 |
| HK1206339A1 (en) | 2016-01-08 |
| IL236087A0 (en) | 2015-02-01 |
| CO7131357A2 (es) | 2014-12-01 |
| WO2013189865A1 (en) | 2013-12-27 |
| UA110310C2 (uk) | 2015-12-10 |
| MA37762B1 (fr) | 2018-04-30 |
| MA37762A1 (fr) | 2017-07-31 |
| US20150133512A1 (en) | 2015-05-14 |
| KR20150011389A (ko) | 2015-01-30 |
| EA201492281A1 (ru) | 2015-04-30 |
| CL2014003241A1 (es) | 2015-03-20 |
| CN104395299A (zh) | 2015-03-04 |
| BR112014030674A2 (pt) | 2017-06-27 |
| IN2014DN09352A (enrdf_load_stackoverflow) | 2015-07-17 |
| CA2869564A1 (en) | 2013-12-27 |
| AU2013279513A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |